THERAPY DOSSIER · th-9cf6a0025ce6

Resolvin D2 loaded into neutrophil membrane-derived nanovesicles (RvD2-HVs)

Drug · Resolvin D2, a specialized pro-resolving lipid mediator, in neutrophil-membrane nanovesicles; not returned by ChEMBL name search.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Resolvin D2, a specialized pro-resolving lipid mediator, in neutrophil-membrane nanovesicles; not returned by ChEMBL name search.
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30673266 ↗2019Reported benefit

Neutrophil Membrane-Derived Nanovesicles Alleviate Inflammation To Protect Mouse Brain Injury from Ischemic Stroke.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57MaleIntravenous1 h after reperfusion (approximately 2 h after onset of occlusion)

Model: Middle cerebral artery occlusion with a silicon rubber-coated 6-0 suture, 60 min occlusion followed by reperfusion

Resolvin D2-loaded neutrophil nanovesicles accumulated in the injured hemisphere, reduced neutrophil infiltration, myeloperoxidase, ICAM-1 and inflammatory cytokines, lowered infarct volume to 16% compared with 46% after PBS, and improved neurological deficit scores.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…